150
Participants
Start Date
September 30, 2011
Primary Completion Date
October 31, 2015
Study Completion Date
December 31, 2015
Intravitreal injection of bevacizumab
1.25 mg per dose, delivered monthly by intravitreal injection for six months
Intravitreal injection of ranibizumab (0.5 mg per dose)
0.5 mg per dose, delivered monthly by intravitreal injection for six months
The Retina Institute, St Louis
Collaborators (1)
Retina Associates of Florida, P.A.
OTHER
Illinois Retina Associates
OTHER
Kresge Eye Institute
OTHER
Long Island Vitreoretinal Consultants
OTHER
Mid Atlantic Retina
OTHER
Retina Associates, Kansas City
OTHER
Massachusetts Eye and Ear Infirmary
OTHER
Barnes Retina Institute
OTHER